ASX biotech stock Neuren Pharmaceuticals Ltd (ASX: NEU) is flying on Monday.
The ASX biotech stock jumped around 30% to $15.92 in morning trade after announcing a major regulatory breakthrough in Europe for its lead drug, DAYBUE.
Despite today's rally, Neuren shares remain down approximately 15% in 2026. Over the past 12 months, however, the ASX biotech stock has gained around 17%, comfortably outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen about 3% over the same period.
So, what has investors so excited?
Image source: Getty Images
A major step towards European approval
Neuren revealed that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorisation for DAYBUE following a re-examination process.
The recommendation now moves to the European Commission, which is expected to make a final decision over the coming months.
If approved, DAYBUE would become the first authorised treatment for the neurobehavioral symptoms of Rett syndrome across all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway.
For the ASX biotech stock, the financial implications could be significant.
Why the decision matters
Neuren is a biotechnology company developing treatments for rare neurological disorders.
Its most advanced medicine is DAYBUE (trofinetide), which has been licensed to Acadia Pharmaceuticals Inc (NASDAQ: ACAD) for commercialisation.
If the European Commission grants marketing approval and DAYBUE launches in Europe, Neuren will receive a US$35 million milestone payment following the first commercial sale.
The company would also become eligible for ongoing royalties on net sales and additional milestone payments if future sales targets are achieved.
That prospect helps explain today's enthusiastic share price reaction.
European approval would open another major market for DAYBUE. Earlier, it launched in the US, creating a fresh revenue stream without Neuren needing to fund sales and marketing itself.
At its FY25 results, the ASX biotech stock reported $65 million in royalty income. It expects further growth in 2026 as DAYBUE sales expand. Acadia has guided for DAYBUE net sales of US$460 to US$490 million this year, implying another strong year of royalty growth for Neuren.
What management said
Neuren CEO Jon Pilcher welcomed the recommendation, saying:
I am so delighted for all stakeholders to see this positive outcome from the CHMP re-examination process recommending marketing authorisation for DAYBU® in the EU. With no approved treatment currently available in the EU, approval of DAYBU® would represent an important step forward for patients, caregivers and the wider Rett syndrome community profoundly impacted by this devastating condition.
What's next for the ASX biotech stock?
While the CHMP recommendation is an important milestone, it is not the final step.
The European Commission must still formally approve the application, with a decision expected in the coming months.
If that happens, the ASX healthcare share would gain access to one of the world's largest pharmaceutical markets. It would also unlock valuable milestone payments and recurring royalty income.
For investors, today's rally reflects growing confidence that DAYBUE is edging closer to another major commercial opportunity.
